72 articles with Castle Biosciences
Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck
Castle Biosciences, Inc. announced the publication of a study highlighting the ability of the DecisionDx®-Melanoma test to accurately determine risk of metastasis in patients with melanoma of the head and neck.
Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions
Validation data from 1,421 patients published in Future Oncology
Castle Biosciences’ DecisionDx-Melanoma Test Identifies High-Risk Melanoma Patients Among Those Traditionally Staged as Low Risk in Newly Published Study
Results from this cumulative validation study are consistent with prior multicenter and single-center, independent prospective studies
Castle Biosciences Announces the Appointment of Genomic Health CFO G. Bradley Cole to Its Board of Directors
Castle Biosciences, Inc. today announced the appointment of G. Bradley Cole to its Board of Directors.
Castle Biosciences, Inc. today announced that Derek Maetzold, President and CEO, will present a company overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28th, 2018 at 10:10 a.m. EST in New York City.
Study Demonstrating Accuracy of DecisionDx-Melanoma Prognostic Test Across Melanoma Tissue Sources Presented at the American Society of Dermatopathology 55th Annual Meeting
Castle Biosciences, Inc. today announced study results showing that the DecisionDx-Melanoma test accurately predicts risk for patients with cutaneous melanoma when using either biopsy or wide local excision (WLE) as the tissue source.
Castle Biosciences to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Castle Biosciences, Inc. today announced that Derek Maetzold will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum.
Study Demonstrates DecisionDx-Melanoma Prognostic Test Accuracy in Patients with Stage II-IIIA Melanoma
Data at the Society for Melanoma Research 2018 Congress highlights benefits of prognostic testing for adjuvant therapy clinical trial designs
Castle Biosciences Announces Medicare Coverage for the DecisionDx-Melanoma Test in Cutaneous Melanoma
Palmetto GBA issues final local coverage determination effective December 3, 2018
Castle Biosciences’ Cutaneous Squamous Cell Carcinoma Prognostic Test Development Progress Highlighted in Oral Presentation at American Society for Dermatologic Surgery Annual Meeting
Aaron Farberg, M.D., Icahn School of Medicine at Mount Sinai, New York, presented the study last week during the Reconstructive, Skin Cancer and Mohs Micrographic Surgery session of the 2018 American Society for Dermatologic Surgery Annual Meeting held in Phoenix.
Castle Biosciences, Inc. today announced that Derek Maetzold, President and CEO, will present at the Baird Global Healthcare Conference on Wednesday, September 5th, 2018 at 11:25 a.m. ET in New York City.
Newly Published Independent Study on a Prospective Cohort Highlights DecisionDx-Melanoma Prognostic Test’s Ability to Accurately Identify High-Risk Melanoma Patients
Results from this second prospective study are consistent with prior four clinical validation studies
Castle Biosciences Presents Data Demonstrating the DecisionDx-Melanoma Test Improved AJCC-Based Risk Prediction for Melanoma Recurrence and Metastasis
Test demonstrated high technical reliability in over 17,000 clinical orders
DecisionDx-Melanoma Test Independently Improved Identification of High-Risk Patients Compared to AJCC Staging in Stage I-II Cutaneous Melanoma
Posters presented at the Real World Dermatology for Physician Assistants and Nurse Practitioners conference also include data demonstrating test’s clinical utility
New Publication Highlights Significant Impact of DecisionDx-Melanoma Prognostic Test on Clinical Management of Patients with Melanoma
Prospective, multicenter study recently published in SKIN The Journal of Cutaneous Medicine
Independent Study Demonstrates Significant and Risk-Appropriate Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management Decisions in Melanoma
New study of 91 patients with cutaneous melanoma is the third recent publication demonstrating that the DecisionDx-Melanoma test impacts one in two clinical management decisions.
The receipt of the New York permit allows patients in that state to benefit from the Company’s DecisionDx®-Melanoma, DecisionDx®-UM and DecisionDx®-PRAME molecular diagnostic tests that provide actionable molecular information to inform patient care decisions.
Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma
The data will be presented during the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in San Diego, CA from February 16-18.
Castle Biosciences Release: DecisionDx-Melanoma Test for Cutaneous Melanoma Validated in Two Prospective Multicenter Study Cohorts to Provide Guidance for Sentinel Lymph Node Biopsy Recommendations
Castle Biosciences announced the presentation of a study highlighting research on a new clinical use for the DecisionDx-Melanoma gene expression profile test to guide sentinel lymph node biopsy (SLNB) recommendations.
The new test will complement Castle Biosciences’ standard-of-care DecisionDx-UM gene expression profile (GEP) test that has been shown to be independent of and superior to mutational analysis in assessing likelihood of metastasis in UM.